Literature DB >> 31476323

Advances in asthma, asthma-COPD overlap, and related biologics in 2018.

Leonard B Bacharier1, Akio Mori2, Hirohito Kita3.   

Abstract

Over the past year, numerous important advances in our understanding of multiple aspects of asthma, ranging from disease pathogenesis to epidemiology to therapeutics, have been reported. This review is a compilation of highlights from articles published largely in the Journal of Allergy and Clinical Immunology and supplemented by articles published elsewhere that have substantially advanced the fields of asthma, chronic obstructive pulmonary disease (COPD), and asthma-COPD overlap and biologic therapies for these disorders. The intention of this article is not to provide a comprehensive review but rather to focus on several areas that have developed quickly and/or received extensive attention from our readers.
Copyright © 2019. Published by Elsevier Inc.

Entities:  

Keywords:  Asthma; asthma-COPD overlap; biologics

Mesh:

Substances:

Year:  2019        PMID: 31476323     DOI: 10.1016/j.jaci.2019.08.021

Source DB:  PubMed          Journal:  J Allergy Clin Immunol        ISSN: 0091-6749            Impact factor:   10.793


  2 in total

1.  Therapeutic efficacy of IL-17A neutralization with corticosteroid treatment in a model of antigen-driven mixed-granulocytic asthma.

Authors:  Katherine E Menson; Madeleine M Mank; Leah F Reed; Camille J Walton; Katherine E Van Der Vliet; Jennifer L Ather; David G Chapman; Bradford J Smith; Mercedes Rincon; Matthew E Poynter
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2020-08-12       Impact factor: 5.464

2.  Comparison of Clinical Characteristics and Short-Term Prognoses Within Hospitalized Chronic Obstructive Pulmonary Disease Patients Comorbid With Asthma, Bronchiectasis, and Their Overlaps: Findings From the ACURE Registry.

Authors:  Jieping Lei; Ting Yang; Chen Liang; Ke Huang; Sinan Wu; Chen Wang
Journal:  Front Med (Lausanne)       Date:  2022-02-25
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.